Home » Clinical Trials » Hemophilia » NCT06224907
NCT06224907

GENEr8-JPN: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Japanese Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions

Study Summary

This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.

Interested in this trial?

Submit an Inquiry

Interventions

Valoctocogene roxaparvovecBIOLOGICAL
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A

Study Locations

FacilityCityStateCountry
Asahikawa Medical University HospitalHokkaidoAsahikawaJapan
Saitama Medical University HospitalSaitamaIruma-gunJapan
Nagoya University HospitalAichiNagoyaJapan
Tokyo Medical University HospitalTokyoShinjuku-kuJapan

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026